Data as of Q4 2025 (Dec 31, 2025)

MRNA

(MRNA)

Financial Statements · SEC EDGAR XBRL

Revenue
$1.94B
-39.9%
Net Income
-$2.82B
+20.8%
EPS
$-7.26
+21.8%
Gross Margin
55.3%
Op. Income
-$3.07B
+22.1%
FCF
-$2.06B
+49.1%
Source: SEC EDGAR XBRL
Breakdown
Revenues
Revenues
Total Revenues
Cost of Revenues
Gross Profit
Operating Expenses & Income
Operating Income
Non-Operating Income/Expense
Net Income
EPS (Basic)
EPS (Diluted)
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
$1.94B
$3.24B
$6.85B
$19.26B
$18.47B
$1.94B
$3.24B
$6.85B
$19.26B
$18.47B
$868.0M
$1.46B
$4.69B
$5.42B
$2.62B
$1.08B
$1.77B
$2.15B
$13.85B
$15.85B
-$3.07B
-$3.94B
-$4.24B
$9.42B
$13.30B
-$2.82B
-$3.56B
-$4.71B
$8.36B
$12.20B
$-7.26
$-9.28
$-12.33
$21.26
$30.31
$-7.26
$-9.28
$-12.33
$20.12
$28.29